Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006, 150(2):285-288 | DOI: 10.5507/bp.2006.043

THE RELEVANCE OF BRAIN NATRIURETIC PEPTIDES INVESTIGATION IN VARIOUS CARDIOVASCULAR DISEASES

Karel Kotaskaa, Jana Popelovab, Marie Tiserovad, Peter Telekesc, Marie Vrzanovad, Jiri Bronskya, Milada Halacovaa, Jiri Kukackaa, Richard Prusaa
a Department of Clinical Biochemistry and Pathobiochemistry, 2nd Medical Faculty, Charles University, Faculty Hospital Motol, Prague, Czech Republic
b Clinic of Cardiac Surgery, Hospital Homolka, Prague
c Clinic of Cardiac Surgery, 2nd Medical Faculty, Charles University, Faculty Hospital Motol, Prague
d Clinic of Internal Medicine, 2nd Medical Faculty, Charles University, Faculty Hospital Motol, Prague

Background: Brain natriuretic peptides are relevant markers of heart impairment.

Aim: We investigated the relevance of investiging brain natriuretic peptides (NT-proBNP, BNP) in monitoring different types of cardiovascular disease (chronic heart failure due to coronary artery disease, cardiomyopathy, acquired valve disease, congenital heart diseases).

Methods: The NT-proBNP assay (Roche) was performed on 280 patients (mean age 49 years; range 20-89 years) and 48 healthy controls (mean age 43 years; range 13-65 years) and BNP assay (Bayer Shionoria) was performed in a subgroup of 42 patients (mean age 50 years; range 20-79 years). Patients were divided into four groups characterized by severity of heart failure according to the New York Heart Association classification.

Results: NT-proBNP concentrations differed in patients with cardiovascular diseases from controls (median 371 ng/l versus 41.5 ng/l, p < 0.0001). The cut off value of NT-proBNP determined in 280 patients with cardiovascular diseases was at 130 ng/l (AUC-area under curve = 0.93; sensitivity 98 %; specificity 79 %). Comparison of NT-proBNP and BNP values in patients showed significant correlation (r = 0.93; p < 0.0001). NT-proBNP showed significant differences between groups.

Conclusions: Measurement of brain natriuretic peptides is useful and relevant in various types of heart diseases including congenital.

Keywords: Brain natriuretic peptides, BNP, NT-proBNP, Cardiovascular diseases, NYHA classification

Received: October 13, 2006; Accepted: November 14, 2006; Published: December 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kotaska, K., Popelova, J., Tiserova, M., Telekes, P., Vrzanova, M., Bronsky, J., ... Prusa, R. (2006). THE RELEVANCE OF BRAIN NATRIURETIC PEPTIDES INVESTIGATION IN VARIOUS CARDIOVASCULAR DISEASES. Biomedical papers150(2), 285-288. doi: 10.5507/bp.2006.043
Download citation

References

  1. Gustafsson F, Badskjaer J, Hansen FS, Poulsen AH, Hildebrant P. Value of N-terminal proBNP in the diagnosis of left ventricular systolic dysfunction in primary care patients referred for echocardiography. Heart Drug 2004; 3:1416. Go to original source...
  2. Seino Y, Ogawa A, Yamashita T, Fukushima M, Ogata K, Fukumoto et al. Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure. Eur J of Heart Failure 2004; 6:295-0. Go to original source... Go to PubMed...
  3. Hammerer-Lercher A, Neubauer E, Muller S, Pachinger O, Puschendorf B, Mair J. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta 2001; 310:1937. Go to original source... Go to PubMed...
  4. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) 1997; 47:28796. Go to original source... Go to PubMed...
  5. Pfister R, Scholz M, Wielckens K, Erdmann E, Schneider CA. Use of NT-proBNP in routine testing and comparison to BNP. Eur J of Heart Failure 2004; 6:289293. Go to original source... Go to PubMed...
  6. Seilhammer JJ, Arfsten A, Miller JA, Lundquist P, Scarborough RM., Lewicki JA, et al. Human and canine gene homologs of porcine brain natriuretic peptide. Biochem Biophys Res Commun 1989; 165(2):6508. Go to original source... Go to PubMed...
  7. Shimizu H, Masuta K, Asada H, Aono K, Sugita K, Sairenji T. Characterization of molecular forms of human pro-brain natriuretic peptide in human plasma. Clin Chim Acta 2002; 334:233239. Go to original source... Go to PubMed...
  8. Mair J, Friedl W, Tomas S, Puschendorf B. Natriuretic peptides in assessment of left-ventricular dysfunction. Scand J Clin Lab Invest 1999; 59:132142. Go to original source...
  9. Belenky A, Smith A, Zhang B, Lin S, Despres N, Wu AHB et al. The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma. Clin Chim Acta 2004; 340 (1-2):16372. Go to original source... Go to PubMed...
  10. Kotaska, K, Popelova, J, Tiserova, M, Telekes, P, Vrzanova, M, Bronsky, J et al.: NT-pro BNP and BNP values in cardiac patients with different degrese of left ventricular systolic dysfunction. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub.2006; 150 (1):125130. Go to original source...
  11. McDonagh TA, Holmer S, Raymond I, Luchner A, Hildebrant P, Dargie HJ. NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. Eur J of Heart Failure 2004; 6:26973. Go to original source... Go to PubMed...
  12. Palladini G, Campana C, Klersy C, Baldulini A, Vadacca G, Perfetti V, et al. Serum N-terminal ProBrain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003; 107:24405. Go to original source... Go to PubMed...